Akademik Veri Yönetim Sistemi
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, cilt.43, sa.4, ss.606-612, 2023 (SCI-Expanded)
Background Type I diabetes mellitus can lead to the development of cognitive dysfunction and anxiety due to chronic hyperglycemia, recurrent hypoglycemia, and micro - and macrovascular complications. It is known that oxytocin and copeptin have effects on neuropsychiatric activities such as learning, memory, and social adaptation and have anxiolytic properties. In this study, we aimed to search the relationship between oxytocin and copeptin levels and cognition and anxiety in patients with type I diabetes mellitus. Methods The study included 39 type I diabetes mellitus patients aged 18-50 years and 39 age- and sex-matched healthy controls. The Montreal cognitive assessment inventory for cognitive assessment and the State and Trait anxiety scales for anxiety assessment were administered to all participants by the same psychologist. Plasma oxytocin and copeptin levels were measured with ELISA kits and compared with the mentioned tests results. Results There were significant differences in oxytocin and copeptin levels between the two groups (p = 0.001). There was no difference in Montreal cognitive assessment and state anxiety scales between the groups, but trait anxiety scales levels were higher in patients (p < 0.001). However, there was no correlation between the oxytocin and copeptin levels and the results of both tests. Conclusions In conclusion, although there was no difference between the groups in terms of cognitive functions and state anxiety, trait anxiety scores were found to be significantly higher in type I diabetes mellitus patients. However, no correlation was found between oxytocin and copeptin levels and these cognition and anxiety scores in either group.